These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18845788)

  • 1. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice.
    Dol-Gleizes F; Paumelle R; Visentin V; Marés AM; Desitter P; Hennuyer N; Gilde A; Staels B; Schaeffer P; Bono F
    Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):12-8. PubMed ID: 18845788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
    Pacher P
    Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):7-9. PubMed ID: 19092136
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
    Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H
    Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice.
    Zhang WJ; Bird KE; McMillen TS; LeBoeuf RC; Hagen TM; Frei B
    Circulation; 2008 Jan; 117(3):421-8. PubMed ID: 18158360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
    Nissen SE; Nicholls SJ; Wolski K; Rodés-Cabau J; Cannon CP; Deanfield JE; Després JP; Kastelein JJ; Steinhubl SR; Kapadia S; Yasin M; Ruzyllo W; Gaudin C; Job B; Hu B; Bhatt DL; Lincoff AM; Tuzcu EM;
    JAMA; 2008 Apr; 299(13):1547-60. PubMed ID: 18387931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
    Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
    Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice.
    van Eenige R; Ying Z; Tambyrajah L; Pronk ACM; Blomberg N; Giera M; Wang Y; Coskun T; van der Stelt M; Rensen PCN; Kooijman S
    J Lipid Res; 2021; 62():100070. PubMed ID: 33766515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid 1 receptor blockade reduces atherosclerosis with enhances reverse cholesterol transport.
    Sugamura K; Sugiyama S; Fujiwara Y; Matsubara J; Akiyama E; Maeda H; Ohba K; Matsuzawa Y; Konishi M; Nozaki T; Horibata Y; Kaikita K; Sumida H; Takeya M; Ogawa H
    J Atheroscler Thromb; 2010 Feb; 17(2):141-7. PubMed ID: 20124735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats.
    Bennetzen MF; Nielsen MP; Richelsen B; Pedersen SB
    Obesity (Silver Spring); 2008 Nov; 16(11):2451-5. PubMed ID: 18719671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat.
    Liu WJ; Jin HY; Park JH; Baek HS; Park TS
    Eur J Pharmacol; 2010 Jul; 637(1-3):70-6. PubMed ID: 20406631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
    Doggrell SA
    Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
    [No Abstract]   [Full Text] [Related]  

  • 13. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.
    Poirier B; Bidouard JP; Cadrouvele C; Marniquet X; Staels B; O'Connor SE; Janiak P; Herbert JM
    Diabetes Obes Metab; 2005 Jan; 7(1):65-72. PubMed ID: 15642077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
    Thornton-Jones ZD; Kennett GA; Benwell KR; Revell DF; Misra A; Sellwood DM; Vickers SP; Clifton PG
    Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haloperidol inhibits the development of atherosclerotic lesions in LDL receptor knockout mice.
    van der Sluis RJ; Nahon JE; Reuwer AQ; Van Eck M; Hoekstra M
    Br J Pharmacol; 2015 May; 172(9):2397-405. PubMed ID: 25572138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
    Duarte C; Alonso R; Bichet N; Cohen C; Soubrié P; Thiébot MH
    Neuropsychopharmacology; 2004 May; 29(5):911-20. PubMed ID: 14694354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.
    Wilck N; Fechner M; Dreger H; Hewing B; Arias A; Meiners S; Baumann G; Stangl V; Stangl K; Ludwig A
    Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1418-26. PubMed ID: 22516063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction.
    Lim SY; Davidson SM; Yellon DM; Smith CC
    Basic Res Cardiol; 2009 Nov; 104(6):781-92. PubMed ID: 19462153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
    Janiak P; Poirier B; Bidouard JP; Cadrouvele C; Pierre F; Gouraud L; Barbosa I; Dedio J; Maffrand JP; Le Fur G; O'Connor S; Herbert JM
    Kidney Int; 2007 Dec; 72(11):1345-57. PubMed ID: 17882151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice.
    Hasan ST; Zingg JM; Kwan P; Noble T; Smith D; Meydani M
    Atherosclerosis; 2014 Jan; 232(1):40-51. PubMed ID: 24401215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.